For example, a phase I clinical trial has been initiated to evaluate the safety and preliminary efficacy of APG-2449, a novel multi-kinase inhibitor in patients with advanced solid tumors, including ALK+ NSCLC refractory to earlier-generation ALK inhibitors [184]. Here, ALK is linked to non-small cell lung carcinoma.